The Management of Polycythaemia Vera

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Thrombo-embolic complications are the primary cause of morbidity and mortality in untreated polycythemia vera (PV).
• Effective management of PV requires controlling hematocrit and platelet counts to mitigate these risks.
• Long-term outcomes of PV include myelofibrotic transformation and a small risk of acute leukemia.

Purpose of the Study:

• To outline optimal management strategies for polycythemia vera.
• To discuss the risks and benefits of various treatment modalities.
• To guide therapeutic choices based on patient age and specific risks.

Main Methods:

• Initial management involves venesection to reduce packed cell volume (PCV).
• Myelosuppressive agents are employed to control proliferation and prevent complications.
• Treatment selection is age-dependent, considering risks of myelofibrotic and leukemic transformation.

Main Results:

• Controlling PCV (<0.45) and platelet count (<400 x 10(9)/L) significantly minimizes thrombo-embolic risk.
• Suppression of megakaryocytic proliferation delays myelofibrotic transformation.
• Certain myelosuppressive agents (chlorambucil, 32P) may enhance leukemic transformation risk.

Conclusions:

• Venesection is a primary initial treatment for reducing PCV.
• Age-appropriate myelosuppressive therapy (32P, busulfan, pipobroman for older patients; interferon-α, anagrelide for younger patients) is crucial.
• Hydroxyurea can be used across age groups but may carry a leukaemogenic risk, necessitating careful consideration.